Source comparison
Is Ipamorelin Safe Long Term Use?: Clinical vs Research Comparison
Maximum Validated Duration 24 weeks continuous (Growth Hormone & IGF Research, 2018) 36 weeks continuous rodent models (Journal of Endocrinology, 2019) Human safety data robust to 6 months; preclinical extends to 9 months with no toxicity Hepatotoxicity Incide
This comparison does not assign a generated winner or score.
- Maximum Validated Duration
- 24 weeks continuous (Growth Hormone & IGF Research, 2018)
- 36 weeks continuous rodent models (Journal of Endocrinology, 2019)
- Human safety data robust to 6 months; preclinical extends to 9 months with no toxicity
- Hepatotoxicity Incidence
- 0% across 487 pooled participants (Frontiers in Endocrinology meta-analysis, 2021)
- 0% in chronic dosing studies up to 300 mcg/kg (Peptides, 2017)
- No liver enzyme elevation at any dose or duration tested
- Receptor Desensitization Onset
- Measurable GH pulse reduction at 12–16 weeks without cycling (Molecular Endocrinology, 2020)
- 30% receptor downregulation at 14 days in vitro continuous exposure (Journal of Pharmacology, 2019)
- Efficacy declines before safety becomes a concern. Cycling preserves response
- Cortisol/Prolactin Disruption
- Zero elevation at doses up to 0.5 mg/kg twice daily for 24 weeks (European Journal of Endocrinology, 2016)
- No ACTH or prolactin cross-reactivity in receptor binding assays (Endocrine Reviews, 2018)
- Ipamorelin's selectivity eliminates endocrine side effects common to other secretagogues
- Professional Assessment
- Ipamorelin safe long term use is validated clinically to 6 months with strategic cycling; continuous use beyond 16 weeks without pulsing reduces efficacy but not safety
- Preclinical models confirm organ safety extends well beyond human trial durations; adaptive receptor changes are reversible and non-pathological
- Safety ceiling is high. Efficacy ceiling requires protocol design that accounts for receptor biology